|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
97,871,000 |
Market
Cap: |
796.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.66 - $22.03 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 20.2 |
Insider 6 Months : 20.2 |
Insider 3/6 Months : 40.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,350,000 |
1,350,000 |
1,350,000 |
7,862,717 |
Total Buy Value |
$20,722,500 |
$20,722,500 |
$20,722,500 |
$80,687,796 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
1 |
5 |
Total Shares Sold |
57,195 |
107,195 |
140,945 |
206,908 |
Total Sell Value |
$623,326 |
$1,183,326 |
$1,830,264 |
$2,842,845 |
Total People Sold |
1 |
1 |
3 |
5 |
Total Sell Transactions |
2 |
3 |
6 |
15 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Palekar Rohan |
Chief Executive Officer |
|
2023-02-05 |
4 |
D |
$13.24 |
$53,993 |
D/D |
(4,078) |
215,351 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-05 |
4 |
D |
$13.24 |
$18,404 |
D/D |
(1,390) |
63,319 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-03 |
4 |
AS |
$12.70 |
$46,848 |
D/D |
(3,592) |
35,368 |
|
62% |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-03 |
4 |
OE |
$3.11 |
$9,330 |
D/D |
3,000 |
38,960 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-01 |
4 |
D |
$12.05 |
$8,375 |
D/D |
(695) |
64,709 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-01 |
4 |
D |
$12.05 |
$4,916 |
D/D |
(408) |
35,960 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2023-02-01 |
4 |
D |
$12.05 |
$8,194 |
D/D |
(680) |
68,158 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-01-03 |
4 |
AS |
$12.51 |
$74,397 |
D/D |
(5,947) |
36,368 |
|
50% |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-11-15 |
4 |
D |
$9.79 |
$30,476 |
D/D |
(3,113) |
68,838 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
71,951 |
|
- |
|
Shah Rajeev M. |
Director |
|
2022-10-18 |
4 |
B |
$7.65 |
$8,971,469 |
I/I |
1,172,741 |
8,955,410 |
2.25 |
53% |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-09-30 |
4 |
D |
$5.79 |
$7,510 |
D/D |
(1,297) |
65,404 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
66,701 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2022-09-28 |
4 |
D |
$5.76 |
$11,624 |
D/D |
(2,018) |
42,315 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,833 |
44,333 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-09-28 |
4 |
D |
$5.76 |
$66,396 |
D/D |
(11,527) |
219,429 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
33,333 |
230,956 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-09-28 |
4 |
D |
$5.76 |
$16,600 |
D/D |
(2,882) |
62,951 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
65,833 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-09-28 |
4 |
D |
$5.76 |
$16,600 |
D/D |
(2,882) |
62,951 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
65,833 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
57,500 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2022-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
38,500 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
57,500 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-09-08 |
4 |
OE |
$1.93 |
$193,000 |
D/D |
100,000 |
197,623 |
|
- |
|
190 Records found
|
|
Page 4 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|